Company intelligence / Profile preview

Pikralida

Ownership: Private
Employees: ~26
Development stage: Preclinical

Overview

Pikralida’s lead human programs—TRX‑03 for poststroke neuroprotection and TRX‑06 for oral snakebite antivenom—have both completed Phase I clinical trials in healthy volunteers. The veterinary antivenom program, TRX‑12, has finished toxicology studies in dogs with formulation work ongoing. The company’s flagship project PKL‑021 targets MMPs but its clinical stage was not explicitly stated.[1][2][3]

Therapeutic areas: OtherNeurology
Modalities: Small molecules[4]Combination drugs/formulations[4]Modern drug delivery systems[4]
Industry: Biotech

Drug pipeline

1 asset

TRX-06

Unknown

Partnerships

Not specifically listed; provides CRO services to national/international pharma companies across Europe/USA including large corporations and SMEs since 2019.[3]

Beyond the preview

Go deeper on Pikralida.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pikralida.

Explore the full profile